Roche Acquires LumiraDx's Point-of-Care Tech to Boost Global Diagnostics

Roche has successfully acquired the Point of Care technology from LumiraDx, subject to receiving regulatory clearances and antitrust approvals. Roche will be able to incorporate its multi-assay point-of-care technology into its worldwide organisation, together with associated R&D, operational, and commercial sites, thanks to the acquisition. With the potential to extend into molecular testing, the platform combines a variety of immunoassay and clinical chemistry assays onto a single device. Roche will be able to increase the amount of decentralised patient care it offers and promote quick and useful diagnostic findings for people all across the world as a result. Global healthcare delivery depends on having access to diagnostic testing, and the LumiraDx platform and technologies will contribute to increasing testing availability, particularly in primary care and low- and middle-income nations.

Roche will keep working with the Bill & Melinda Gates Foundation to create a novel, quick point-of-care molecular TB test in order to further enhance the platform's molecular diagnostic capabilities. With the goal of achieving global epidemic control objectives, this test attempts to improve TB diagnosis and treatment. At the close of 2023, an acquisition agreement will be executed.